Compare Occidental Petroleum Corporation (OXY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs BIO-TECHNE Corp — how do they compare? Occidental Petroleum Corporation trades at $61.25 (market cap $60.63B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Occidental Petroleum Corporation is far larger — about 5.3× BIO-TECHNE Corp's market cap, and Occidental Petroleum Corporation pays the higher dividend (1.85%). Which is the better fit depends on your goals.
| OXY | TECH | |
|---|---|---|
Market Cap | $60.63B | $11.34B |
Sector | Energy | Health |
52-Week High | $66.24 | $72.48 |
52-Week Low | $38.92 | $43.31 |
Enterprise Value | $79.39B | $11.36B |
Dividend Yield | 1.85% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $60.65, up 1.02% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 30.32% net income margin and 21.46% ROE, while trading at reasonable valuations (P/E 17.89, EV/EBITDA 5.59). Recent earnings beats and improving balance sheet with debt reduction to $25.32 billion support positive sentiment.
OXY presents a compelling opportunity with analyst consensus target of $68.67 (13% upside) and 50% buy ratings. Key catalysts include continued debt reduction, projected 2026 net margin expansion to 30.31%, and oil price tailwinds. Risks include oil price volatility, execution on production targets, and macroeconomic headwinds affecting energy demand.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
